EP 4291238 A1 20231220 - A PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING IMMUNE RESPONSE AGAINST CANCER
Title (en)
A PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING IMMUNE RESPONSE AGAINST CANCER
Title (de)
PHARMAZEUTISCHE KOMBINATION UND VERFAHREN ZUR ÜBERWINDUNG DER IMMUNSUPPRESSION ODER STIMULATION DER IMMUNREAKTION GEGEN KREBS
Title (fr)
COMBINAISON PHARMACEUTIQUE ET MÉTHODE POUR SURMONTER LA SUPPRESSION IMMUNITAIRE OU STIMULER UNE RÉPONSE IMMUNITAIRE CONTRE LE CANCER
Publication
Application
Priority
CN 2021076503 W 20210210
Abstract (en)
[origin: WO2022170557A1] It relates to a method of overcoming immune suppression in tumor microenvironment or stimulating immune response against cancer, comprising administering to a subject a combination of a histone deacetylase (HDAC) inhibitor and a tyrosine kinase inhibitor (TKI).
IPC 8 full level
A61K 45/00 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP)
A61K 31/167 (2013.01); A61K 31/4406 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/502 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2022170557 A1 20220818; CN 116887864 A 20231013; EP 4291238 A1 20231220; JP 2024508395 A 20240227; TW 202231275 A 20220816
DOCDB simple family (application)
CN 2021076503 W 20210210; CN 202180093554 A 20210210; EP 21925220 A 20210210; JP 2023547769 A 20210210; TW 110116080 A 20210504